[Abciximab], PMID: 17465067
How abciximab might be clinically useful, PMID: 27519521
Cryo-Electron Microscopy Structure of the αIIbβ3-Abciximab Complex, PMID: 31969014
Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions, PMID: 21204736
ABCIXIMAB: a new antiaggregant used in angioplasty, PMID: 8833561
Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation, PMID: 10724797
Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution, PMID: 29305853
Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease, PMID: 7528131
A review of intracoronary abciximab in percutaneous coronary interventions--where are we now and where do we go from here?, PMID: 23957238
Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions, PMID: 21942506
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention, PMID: 20234778
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting, PMID: 30845955
Current status of cardiac surgery in the abciximab-treated patient, PMID: 10966006
Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction, PMID: 30418157
Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact, PMID: 33041442
Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction, PMID: 14727961
Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention, PMID: 30460974
Intracoronary Abciximab in Diabetic STEMI Patients: Questionable Benefit, Proven Harm, PMID: 27515334
Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?, PMID: 16891291
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients, PMID: 27366874
Clinical experience in coronary bypass surgery for abciximab-treated patients, PMID: 10966008
Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications, PMID: 11033455
Reply, PMID: 29371038
On the use of abciximab in percutaneous coronary intervention, PMID: 21827726
Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment, PMID: 30154253
Cangrelor or Abciximab as First Choice in Cardiogenic Shock, PMID: 29217012
Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis, PMID: 31542257
In situ administration of abciximab for thrombus resolution during intracranial bypass surgery: case report, PMID: 29350605
Understanding the complexity of abciximab-related thrombocytopenia, PMID: 20135055
Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial, PMID: 22447888
Use of intravenous abciximab as adjunctive therapy for carotid angioplasty and stent placement, PMID: 12745860
Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock, PMID: 29217013
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials, PMID: 15827315
Bilateral subconjunctival hemorrhage secondary to abciximab use: case report, PMID: 29267537
Abciximab and excessive bleeding in patients undergoing emergency cardiac operations, PMID: 9485247
Thromboaspiration and IIb/IIIa therapy in STEMI: abciximab redux?, PMID: 24078419
[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents], PMID: 9806003
Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?, PMID: 11773572
Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis, PMID: 12112910
Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis, PMID: 20516508
Abciximab extends treatment window for stroke, PMID: 12849109
Intracoronary abciximab in STEMI using local drug delivery catheter - single center experience, PMID: 23809377
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up, PMID: 17251257
Periprocedural abciximab administration in ST elevation myocardial infarction patients. Effect on severe microvascular obstruction beyond the restoration of epicardial coronary flow by primary angioplasty, PMID: 17971662
Readministration of abciximab in percutaneous coronary intervention, PMID: 10745525
Concentration-dependent effect of abciximab on platelets and neutrophils in a model of cardiopulmonary bypass, PMID: 17312858
High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study, PMID: 24831494
Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction, PMID: 12587942
Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor, PMID: 16015412
Stenting and abciximab in primary angioplasty: a review of current status, PMID: 16320920
Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study., PMID:40525526
Coronary artery ectasia presenting as acute coronary syndrome and misinterpreted as coronary artery perforation: Case report., PMID:40324275
Red blood cell aggregation within a blood clot causes platelet-independent clot shrinkage., PMID:40238947
Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study., PMID:40074268
Catheter-Directed Thrombolysis in the Management of Thrombotic Peripheral Artery Occlusions-Acute and Mid-Term Clinical Outcomes., PMID:39407791
Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction., PMID:39335537
Role of Intracoronary Adrenaline in the Treatment of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention., PMID:38883139
The Relationship of Coronary Thrombus Burden and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Score in Patients With ST-Segment Elevation Myocardial Infarction., PMID:38644774
Qualitative classification of thrombus images as a way to improve quantitative analysis of thrombus formation in flow chamber assays., PMID:38466712
A novel technique to quantify the kinetics of blood clot contraction based on the expulsion of fluorescently labeled albumin into serum., PMID:38401713
Derivation and validation of the incomplete ST-segment resolution score and its usefulness for treatment with glycoprotein IIb-IIIa inhibitors., PMID:38149704
A Fatal Case of Acute Thrombotic Occlusion in More Than 3 Epicardial Coronary Arteries Associated with the Yasmin Oral Contraceptive., PMID:38146410
Adverse Drug Effect Profiles of Gp2b/3a Inhibitors: A Comparative Review of the Last Two Decades., PMID:38143693
Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)., PMID:38063187
Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis., PMID:37760122
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion., PMID:37682072
Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature., PMID:37077602
Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis., PMID:36961079
[Comparison of the predictive value of the modified CADILLAC, GRACE and TIMI risk scores for the risk of short-term death in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention]., PMID:36916344
Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome., PMID:36682715
An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives., PMID:36637623
Comparison of Different Risk Scores for Prediction of In-Hospital Mortality in STEMI Patients Treated with PPCI., PMID:36619804
Targeting integrin pathways: mechanisms and advances in therapy., PMID:36588107
GPIIb/IIIa Receptor Targeted Rutin Loaded Liposomes for Site-Specific Antithrombotic Effect., PMID:36413707
Anti-Platelet Peptides Targeting αIIbβ3 Outside-In Signaling Pathway., PMID:36380406
It's the water! The open and shut case of drug-induced integrin activation., PMID:36113425
Efficient delivery of abciximab using mesoporous silica nanoparticles: In-vitro assessment for targeted and improved antithrombotic activity., PMID:35917688
Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials., PMID:35685429
Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis., PMID:35356949
Antiplatelet agents for chronic kidney disease., PMID:35224730
Alveolar Hemorrhage during Abciximab Infusion., PMID:35082871
A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES., PMID:35071113
A New Score for Determining Thrombus Burden in STEMI Patients: The MAPH Score., PMID:35018837
Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab., PMID:34984684
Ruptured Proximal Anterior Cerebral Artery Aneurysm Treated with Flow Diverter., PMID:34859825
Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications., PMID:34847829
Mechanical clot dissolution technique for surgical clip-related occlusions: An emergent triple-step approach., PMID:34667905
Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms., PMID:34474088
Acute phase segmental radial strain correlates with recovery and late gadolinium extent in ST-elevation myocardial infarction (STEMI): analysis of the abciximab intracoronary versus intravenously drug application in STEMI substudy., PMID:34341734
Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction., PMID:34031019
Impact of CADILLAC and GRACE risk scores on short- and long-term clinical outcomes in patients with acute myocardial infarction., PMID:33947628
Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients., PMID:33840346
Electron microscopy shows that binding of monoclonal antibody PT25-2 primes integrin αIIbβ3 for ligand binding., PMID:33760023
Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review., PMID:33726948
Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead., PMID:33677829
Lysis of arterial thrombi by perfusion of N,N'-Diacetyl-L-cystine (DiNAC)., PMID:33630932
Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with ST-segment elevation myocardial infarction., PMID:33623858
Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention., PMID:33560898